Wednesday, 30 October 2019

Sjogrens Syndrome in the News

See https://www.ncl.ac.uk/press/articles/latest/2019/10/sjogrensyndromebreakthrough/


Wednesday, 16 October 2019

Synovial Fibroblasts


 

Faculty Seminar

 

Speaker:

Kirsten Klein

Centre of Experimental Rheumatology, University Hospital Zurich

 

 

Venue:

MED.L2.6

 

Date:

Thursday 17th October 2019

 

Time:

11.30 – 12.30

 

Kirsten will present:

 

"Epigenetics of synovial fibroblasts"

 

Synovial fibroblasts are the most abundant stromal cells in joints that promote inflammation and drive joint destruction in rheumatoid arthritis. Synovial fibroblasts from different joint localizations exhibit profound differences in their expression profiles, which translate into a joint specific enrichment of arthritis relevant pathways, molecules and functional differences. Epigenetic factors act as intermediaries to link genetic and environmental risk factors to altered gene expression levels in a cell type-specific manner. Epigenetic mechanisms define the positional identity of synovial fibroblasts and underlie their role in persistent inflammation. Interfering with epigenetic modifications and their related epigenetic enzymes have therapeutic potential in rheumatoid arthritis.

 

Chair:

Professor John Isaacs

 

 

 

 

 

 

 

Friday, 11 October 2019

PSORT Showcase - 18th November 2019, Royal College of Physicians, London


The PSORT (Psoriasis Stratification to Optimise Relevant Therapy) Stratified Medicine Consortium will host a one day Showcase event at the Royal College of Physicians, London to highlight its progress, achievements and plans for the future.

Formed by dermatologists, industry partners (including pharmaceutical companies), the British Association of Dermatologists and importantly, the Psoriasis Association, PSORT was established to determine whether it could predict which patients with psoriasis would respond best to a particular biologic drug. This, rather than the existing system of "trial and error" prescribing, would allow new treatment plans to be devised that would be personalised to the individual with psoriasis.  If successful, such stratification might also achieve cost savings to the NHS and aid the pharmaceutical industry in the development of new drugs for psoriasis.

The Showcase will focus on how the key aspects of our programme have worked together for patient benefit. It will feature invited lectures by leading international speakers (academic, clinical, industry) interspersed amongst updates from scientists and clinicians from the PSORT team. These will be supplemented by a lunchtime poster exhibition. The day concludes with a networking wine reception.

The Showcase is free to attend and is open to the research community, industry, founders and patients alike.

Join us as we discuss how our findings might be of relevance to you. 

To register, please use the BAD registration link  https://www.eventsforce.net/bad/277/home

 

 

Friday, 27 September 2019

What Can Patients Tell Us About Sjӧgren's Syndrome?

Apparently, they can tell us quite a lot. 

Three international cohorts, two clinical trials including patient reported symptoms, clinical and  biological data, proteomics and transcriptomics. 

See the latest paper in The Lancet Rheumatology.


Thursday, 26 September 2019

Prof Andy Mellor on Immunotherapy for Chronic Diseases


PI Seminar Series


Speaker:

Professor Andy Mellor

 

Venue:

Dental Lecture Theatre E

 

Date:

Wednesday 2nd October 2019

 

Time:

13:00 – 14:00

 

Andy Mellor will present:

 

"Immunotherapy for chronic diseases: Can we stop the wheels spinning?"

 

Chronic conditions create huge and growing health care burdens worldwide. Chronic tissue inflammation is a hallmark of many chronic conditions, including cancers, chronic infections, autoimmune cardiovascular and neuro-inflammatory diseases and allergies.   Inflammation activates immune cells to incite protective responses against pathogenic organisms. If unresolved, inflammation causes progressive immune dys-function and increased risk of tissue damage and disease. Immune checkpoints discovered in mouse models of cancer offer new insights into the causes and consequences of chronic inflammation and how to manipulate inflammation to modify immune balance for clinical benefit. Our recent work on mouse models of cancer and autoimmune syndromes provides fresh perspectives on how to manipulate the immune system to prevent and treat chronic conditions

 

 

Chair:

Professor Mark Walker